Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Research & Development data on file, last reported at $21.5 million in Q1 2026.

• Quarterly Research & Development fell 38.31% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.8 million (down 43.99% YoY) and the FY2025 annual result came in at $112.2 million, down 42.5% from the prior year.
• Research & Development fell to $21.5 million in Q1 2026, from $24.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $58.7 million in Q2 2024 to a low of $21.5 million in Q1 2026.
• A 5-year average of $39.3 million and a median of $38.2 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 37.91% — and 2025, when it plunged 49.58%.
• Tracing ARCT's Research & Development over 5 years: stood at $27.0 million in 2022, then jumped by 35.73% to $36.6 million in 2023, then increased by 19.55% to $43.8 million in 2024, then plunged by 44.09% to $24.5 million in 2025, then retreated by 12.05% to $21.5 million in 2026.
• The last three Research & Development figures came in at $21.5 million (Q1 2026), $24.5 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.